This study aims to elucidate the role of the ZFAS1/STAT3 signaling axis in mediating imatinib resistance in CML by promoting metabolic reprogramming, with a particular focus on alterations in glucose metabolism. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.